Article

Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variant

2021-12-28

Abstract excerpt

<h4>Background: </h4> We carried out a literature search for summarizing currently published evidence on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant neutralizing properties of serum or plasma collected from recipients of coronavirus disease 2019 (COVID-19) vaccines. <h4>Methods: </h4>: An electronic search was conducted in Medline and Scopus, using the keywords “vaccine...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 56d435b9-2075-5cd3-904d-6fb2cd8b629c
DOI: 10.21203/rs.3.rs-1207848/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variantDOI 10.21203/rs.3.rs-1207848/v1Read

SARS-CoV-2 vaccine-breakthrough infections (VBIs) by Omicron (B.1.1.529) variant and consequences in structural and functional impactSemantic proximity Read

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concernSemantic proximity Read

<strong>Efficacy of COVID-19 Vaccines Against the Omicron Variant of SARS-CoV-2</strong>Semantic proximity Read

Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity) post 6-monthsSemantic proximity Read

Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera.Semantic proximity Read

SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesSemantic proximity Read

Facing the Omicron variant – How well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic reviewSemantic proximity Read

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 VaccineSemantic proximity Read

Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variantsSemantic proximity Read

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineSemantic proximity Read

Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysisSemantic proximity Read

Expert Review of Global Real-World Data on COVID-19 Vaccine Booster Effectiveness & Safety During the Omicron-dominant Phase of the PandemicSemantic proximity Read